Effects of Proton Pump Inhibitors on Patient Survival in Patients Undergoing Maintenance Hemodialysis

Overview

Journal J Clin Med

Specialty General Medicine

Date 2023 Jul 29

PMID 37510864

Authors

Seok Hui Kang

Gui Ok Kim

Bo Yeon Kim

Eun Jung Son

Jun Young Do

Affiliations

Soon will be listed here.

Abstract

Data to draw definite conclusions regarding the association between proton pump inhibitor (PPI) and all-cause mortality in patients undergoing hemodialysis (HD) remain insufficient. The object of this retrospective study was to assess the impact of PPIs on patient survival within a substantial cohort of individuals receiving maintenance HD. To achieve this, the study employed laboratory and clinical data sourced from the 4th, 5th, and 6th National HD Quality Assessment Programs. The programs included patients undergoing maintenance HD (n = 54,903). Based on the PPI prescription data collected over the 6-month HD quality assessment, the patients were categorized into three groups: Group 1, comprising individuals with not prescription; Group 2, consisting of patients prescribed PPIs for less than 90 days; and Group 3, comprising patients prescribed PPIs for 90 days or more. The respective number of patients in Groups 1, 2, and 3 was 43,059 (78.4%), 5065 (9.2%), and 6779 (12.3%), respectively. Among the study groups, the 5-year survival rates were as follows: Group 1-70.0%, Group 2-68.4%, and Group 3-63.0%. The hazard ratio for Group 3 was 1.09 (95% CI, 1.04 to 1.15; < 0.001) and 1.10 (95% CI, 1.03 to 1.18; = 0.007) compared to Groups 1 or 2 based on multivariable analysis. Multivariable analyses revealed a lower rate of patient survival in Group 3 compared to the other groups, while Groups 1 and 2 exhibited similar patient survival rates. Our study revealed a significant association between long-term PPI usage and increased mortality among patients undergoing HD. However, distinct trends were observed in subgroup analyses. The association between long-term PPI usage and mortality was prominent in patients who did not have a high gastrointestinal burden or comorbidities. Meanwhile, this association was not observed in patients who did have a high gastrointestinal burden or comorbidities.

References

Battistella M, Jandoc R, Ng J, McArthur E, Garg A . A Province-wide, Cross-sectional Study of Demographics and Medication Use of Patients in Hemodialysis Units Across Ontario. Can J Kidney Health Dis. 2018; 5:2054358118760832. PMC: 5858734. DOI: 10.1177/2054358118760832. View

Misra P, Alam A, Lipman M, Nessim S . The relationship between proton pump inhibitor use and serum magnesium concentration among hemodialysis patients: a cross-sectional study. BMC Nephrol. 2015; 16:136. PMC: 4535779. DOI: 10.1186/s12882-015-0139-9. View

Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View

Scarpignato C, Gatta L, Zullo A, Blandizzi C . Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016; 14(1):179. PMC: 5101793. DOI: 10.1186/s12916-016-0718-z. View

de Francisco A, Varas J, Ramos R, Merello J, Canaud B, Stuard S . Proton Pump Inhibitor Usage and the Risk of Mortality in Hemodialysis Patients. Kidney Int Rep. 2018; 3(2):374-384. PMC: 5932134. DOI: 10.1016/j.ekir.2017.11.001. View

Mikolasevic I, Milic S, Stimac D, Zaputovic L, Lukenda Zanko V, Gulin T . Is there a relationship between hypomagnesemia and proton-pump inhibitors in patients on chronic hemodialysis?. Eur J Intern Med. 2016; 30:99-103. DOI: 10.1016/j.ejim.2016.01.026. View

Daugirdas J . Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol. 1993; 4(5):1205-13. DOI: 10.1681/ASN.V451205. View

Abraham N, Hlatky M, Antman E, Bhatt D, Bjorkman D, Clark C . ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and.... Circulation. 2010; 122(24):2619-33. DOI: 10.1161/CIR.0b013e318202f701. View

Levey A, Eknoyan G . Cardiovascular disease in chronic renal disease. Nephrol Dial Transplant. 1999; 14(4):828-33. DOI: 10.1093/ndt/14.4.828. View

10.

Kim H, Jhee J, Joo Y, Yang K, Jung J, Shin J . Clinical significance of hemodialysis quality of care indicators in very elderly patients with end stage kidney disease. J Nephrol. 2022; 35(9):2351-2361. DOI: 10.1007/s40620-022-01356-3. View

11.

Savarino V, Dulbecco P, De Bortoli N, Ottonello A, Savarino E . The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal. Eur J Intern Med. 2016; 37:19-24. DOI: 10.1016/j.ejim.2016.10.007. View

12.

Kosedo I, Tokushige A, Takumi T, Yoshikawa A, Teraguchi K, Takenouchi K . Use of proton pump inhibitors is associated with an increase in adverse cardiovascular events in patients with hemodialysis: Insight from the kids registry. Eur J Intern Med. 2019; 72:79-87. DOI: 10.1016/j.ejim.2019.11.002. View

13.

Desbuissons G, Mercadal L . Use of proton pump inhibitors in dialysis patients: a double-edged sword?. J Nephrol. 2020; 34(3):661-672. DOI: 10.1007/s40620-020-00808-y. View

14.

Drueke T, Parfrey P . Summary of the KDIGO guideline on anemia and comment: reading between the (guide)line(s). Kidney Int. 2012; 82(9):952-60. DOI: 10.1038/ki.2012.270. View

15.

Makunts T, Alpatty S, Lee K, Atayee R, Abagyan R . Proton-pump inhibitor use is associated with a broad spectrum of neurological adverse events including impaired hearing, vision, and memory. Sci Rep. 2019; 9(1):17280. PMC: 6872761. DOI: 10.1038/s41598-019-53622-3. View

16.

Vangala C, Niu J, Lenihan C, Mitch W, Navaneethan S, Winkelmayer W . Proton Pump Inhibitors, Histamine-2 Receptor Antagonists, and Hip Fracture Risk among Patients on Hemodialysis. Clin J Am Soc Nephrol. 2018; 13(10):1534-1541. PMC: 6218825. DOI: 10.2215/CJN.02190218. View

17.

Ago R, Shindo T, Banshodani M, Shintaku S, Moriishi M, Masaki T . Hypomagnesemia as a predictor of mortality in hemodialysis patients and the role of proton pump inhibitors: A cross-sectional, 1-year, retrospective cohort study. Hemodial Int. 2016; 20(4):580-588. DOI: 10.1111/hdi.12437. View

18.

Targownik L, Fisher D, Saini S . AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review. Gastroenterology. 2022; 162(4):1334-1342. DOI: 10.1053/j.gastro.2021.12.247. View

19.

Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi J . Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005; 43(11):1130-9. DOI: 10.1097/01.mlr.0000182534.19832.83. View

20.

Alhosaini M, Walter J, Singh S, Dieter R, Hsieh A, Leehey D . Hypomagnesemia in hemodialysis patients: role of proton pump inhibitors. Am J Nephrol. 2014; 39(3):204-9. DOI: 10.1159/000360011. View